Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/10/2022* -- Results Q3 2022 -- -0.44 --
08/04/2022 -- Results Q2 2022 -0.44 -0.45 1.12%
05/12/2022 -- Results Q1 2022 -0.43 -0.35 -24.64%
03/14/2022 -- Results Q4 2021 -0.55 -0.53 -3.77%
11/10/2021 -- Results Q3 2021 -0.63 -0.68 7.35%
08/10/2021 -- Results Q2 2021 -0.65 -0.66 1.52%
05/10/2021 -- Results Q1 2021 -0.60 -0.56 -7.14%
03/18/2021 -- Results Q4 2020 -1.10 -1.79 38.22%
*Estimated Date/Time

Earnings

Next Report Date 11/10/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/04/2022
Beat/Miss Upgrade
Return Since -40.36%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Sigilon Therapeutics Inc is a clinical stage biopharmaceutical company. The company is developing a new class of therapeutics and functional cures for patients with chronic diseases by providing stable and durable levels of therapeutic molecules to patients. Its lead product candidate, SIG-001, prevents bleeding in patients with moderate-severe to severe Hemophilia A.
URL https://www.sigilon.com
Investor Relations URL https://ir.sigilon.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 10, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
--
--
--
-94.25%
-81.88%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-22.42%
-36.32%
-81.84%
12.49%
51.87%
218.8%
27.43%
-39.11%
-52.39%
-67.80%
-28.59%
-49.84%
-47.69%
-93.17%
229.0%
-48.60%
-32.46%
-87.17%
63.37%
16.67%
-79.93%
-17.17%
8.91%
-45.97%
-70.79%
-44.57%
-56.37%
48.58%
-52.96%
5.47%
10.67%
-77.09%
24.44%
As of September 26, 2022.

Profile

Edit
Sigilon Therapeutics Inc is a clinical stage biopharmaceutical company. The company is developing a new class of therapeutics and functional cures for patients with chronic diseases by providing stable and durable levels of therapeutic molecules to patients. Its lead product candidate, SIG-001, prevents bleeding in patients with moderate-severe to severe Hemophilia A.
URL https://www.sigilon.com
Investor Relations URL https://ir.sigilon.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 10, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter SGTX Tweets